CIK 2077247
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 97.48% | 24 |
| Unclassified | 2.52% | 2 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | PCVX | Vaxcyte, Inc. | Health Care | 9.06% |
| 2 | DFTX | Definium Therapeutics, Inc. | Health Care | 7.73% |
| 3 | LBRX | LB PHARMACEUTICALS INC | Health Care | 7.66% |
| 4 | MIRM | Mirum Pharmaceuticals, Inc. | Health Care | 7.25% |
| 5 | NRIX | Nurix Therapeutics, Inc. | Health Care | 6.36% |
| 6 | XENE | Xenon Pharmaceuticals Inc. | Health Care | 6.02% |
| 7 | RVMD | Revolution Medicines, Inc. | Health Care | 5.61% |
| 8 | RCUS | Arcus Biosciences, Inc. | Health Care | 5.33% |
| 9 | IMCR | Immunocore Holdings plc | Health Care | 4.84% |
| 10 | CYTK | CYTOKINETICS INC | Health Care | 4.65% |
24/26 names classified · sector 97.5% of weight · industry 97.5% · mkt cap 92.7%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 97.5% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/26 names) · unclassified 100.0%: PCVX, DFTX, LBRX, MIRM, NRIX, XENE, RVMD, RCUS, IMCR, CYTK +16 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | PCVXVAXCYTE INC | 662,470 | $38M | 9.1% | TRIM −10% |
| 2 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 1,738,110 | $33M | 7.7% | NEW |
| 3 | LBRXLB PHARMACEUTICALS INC | 1,319,362 | $33M | 7.7% | TRIM −5% |
| 4 | MIRMMIRUM PHARMACEUTICALS INC | 333,312 | $31M | 7.2% | ADD 946% |
| 5 | NRIXNURIX THERAPEUTICS INC | 1,743,220 | $27M | 6.4% | HOLD |
| 6 | XENEXENON PHARMACEUTICALS INC | 440,000 | $26M | 6.0% | TRIM −26% |
| 7 | RVMDREVOLUTION MEDICINES INC | 245,000 | $24M | 5.6% | NEW |
| 8 | RCUSARCUS BIOSCIENCES INC | 1,047,935 | $23M | 5.3% | ADD 14% |
| 9 | IMCRIMMUNOCORE HLDGS PLC | 682,597 | $21M | 4.8% | HOLD |
| 10 | CYTKCYTOKINETICS INC | 300,000 | $20M | 4.7% | NEW |
| 11 | SNDXSYNDAX PHARMACEUTICALS INC | 701,821 | $16M | 3.9% | NEW |
| 12 | NGNENEUROGENE INC | 782,787 | $16M | 3.7% | HOLD |
| 13 | IVAINVENTIVA SA | 2,657,997 | $15M | 3.5% | HOLD |
| 14 | IKTINHIBIKASE THERAPEUTICS INC | 8,057,345 | $14M | 3.2% | ADD 30% |
| 15 | FDMT4D MOLECULAR THERAPEUTICS IN | 1,302,917 | $12M | 2.9% | NEW |
| 16 | XFORX4 PHARMACEUTICALS INC | 2,571,478 | $11M | 2.5% | HOLD |
| 17 | IMVTIMMUNOVANT INC | 414,054 | $10M | 2.4% | ADD 72% |
| 18 | DSGNDESIGN THERAPEUTICS INC | 852,013 | $9M | 2.1% | NEW |
| 19 | CAMPCAMP4 THERAPEUTICS CORP | 1,939,563 | $9M | 2.0% | TRIM −2% |
| 20 | NERVMINERVA NEUROSCIENCES INC | 1,419,000 | $9M | 2.0% | NEW |
| 21 | PMNPROMIS NEUROSCIENCES INC | 557,103 | $7M | 1.7% | NEW |
| 22 | SLGLSOL GEL TECHNOLOGIES | 85,496 | $7M | 1.6% | NEW |
| 23 | IPSCCENTURY THERAPEUTICS INC | 2,449,993 | $6M | 1.3% | NEW |
| 24 | VTVTVTV THERAPEUTICS INC | 139,578 | $6M | 1.3% | TRIM −40% |
| 25 | FTHSENSEI BIOTHERAPEUTICS INC | 125,000 | $4M | 0.9% | NEW |
| 26 | IRDOPUS GENETICS INC | 500,000 | $2M | 0.5% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| PCVXVAXCYTE INC | — | — | — | — | 737K | 662K | $38M |
| DFTXDEFINIUM THERAPEUTICS INC COM SHS | — | — | — | — | — | 1.7M | $33M |
| LBRXLB PHARMACEUTICALS INC | — | — | — | — | 1.4M | 1.3M | $33M |
| MIRMMIRUM PHARMACEUTICALS INC | — | — | — | — | 32K | 333K | $31M |
| NRIXNURIX THERAPEUTICS INC | — | — | — | — | 1.7M | 1.7M | $27M |
| XENEXENON PHARMACEUTICALS INC | — | — | — | — | 597K | 440K | $26M |
| RVMDREVOLUTION MEDICINES INC | — | — | — | — | — | 245K | $24M |
| RCUSARCUS BIOSCIENCES INC | — | — | — | — | 916K | 1.0M | $23M |
| IMCRIMMUNOCORE HLDGS PLC | — | — | — | — | 683K | 683K | $21M |
| CYTKCYTOKINETICS INC | — | — | — | — | — | 300K | $20M |
| SNDXSYNDAX PHARMACEUTICALS INC | — | — | — | — | — | 702K | $16M |
| NGNENEUROGENE INC | — | — | — | — | 785K | 783K | $16M |
| IVAINVENTIVA SA | — | — | — | — | 2.7M | 2.7M | $15M |
| IKTINHIBIKASE THERAPEUTICS INC | — | — | — | — | 6.2M | 8.1M | $14M |
| FDMT4D MOLECULAR THERAPEUTICS IN | — | — | — | — | — | 1.3M | $12M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
